Our pipeline products address the entire spectrum of the wound-care process for chronic wounds, from key first steps to the completion of closure.
Our personalised solution that promotes the complete closure of chronic wounds, including vascular leg ulcers.
Our scalable treatment for chronic leg ulcers that are not responding to standard of care, using automated manufacturing.
Our easy-to-use, and painless enzymatic debridement spray clears dead tissue to support physiological healing processes.
Our first-in-class autologous cell grafting medical device is rapid, cost-effective, intuitive, and safe to use, enabling personalised treatment of wounds at the point-of-care.
healiva® 003: Enzymatic Debrider spray cleans wounds, creates barrier to infection, and kickstart physiological repair mechanisms.
healiva® 002/004 Cell therapy interventions for early stage chronic wounds (Chronic Venous Leg Ulcers (VLU) & Diabetic Foot Ulcers /DFU).
healiva® 001 Cell therapy interventions for severe, hard to heal wounds (Recalcitrant Venous Leg Ulcers).
healiva® is a Bioseutica backed innovative Swiss startup venture located in Lugano combining digital health, enzyme technology and cell therapy to deliver personalised and precision solutions for regenerative biology.